drugset / Trial / NCT01053312

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

NCT01053312

Phase 3 Completed 7 enrolled GE Healthcare i3 Statprobe · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This study will determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).

Timeline

Start
2009-12
Primary completion
2010-07
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Flutemetamol Diagnostic / imaging agent 10 ug Intravenous
Subject Flutemetamol Diagnostic / imaging agent 185 mbq Intravenous